Kilitch Drugs (India) (NSE:KILITCH) Total Current Liabilities: ₹1,216 Mil (As of Mar. 2026)


NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
85 GF Score
Price ₹184.24
GF Value ₹226.20
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Total Current Liabilities?

Kilitch Drugs (India) NSE:KILITCH +0.61% 85 Total Current Liabilities is ₹1,216 Mil as of Mar. 2026. GuruFocus rates NSE:KILITCH with a GF Score™ of 85/100 and a GF Value™ of ₹226.20 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Kilitch Drugs (India)'s total current liabilities for the quarter that ended in Mar. 2026 was ₹1,216

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Kilitch Drugs (India) Total Current Liabilities Related Terms

Kilitch Drugs (India) Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) Total Current Liabilities Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 692.79 688.73 642.16 843.10 1,215.99

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 843.10 0.00 828.97 0.00 1,215.99
NSE:KILITCH
85GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Kilitch Drugs (India)'s Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=862.124+301.055
+Other Current Liabilities+Current Deferred Liabilities
=52.813+0
=1,216

Kilitch Drugs (India)'s Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=862.124+301.055
+Other Current Liabilities+Current Deferred Liabilities
=52.813+0
=1,216

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of ₹1,216 Mil mean?
Kilitch Drugs (India) (NSE:KILITCH) has a Total Current Liabilities of ₹1,216 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Kilitch Drugs (India) and its competitors.
Is Kilitch Drugs (India)'s Total Current Liabilities too high?
Kilitch Drugs (India)'s current Total Current Liabilities is ₹1,216 Mil. Overall, Kilitch Drugs (India) has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Total Current Liabilities compare to ZTS and UTHR?
Kilitch Drugs (India)'s Total Current Liabilities of ₹1,216 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current Total Current Liabilities is ₹1,216 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.20, compared to a current price of ₹184.24 — trading 18.5% below its estimated fair value. The current Total Current Liabilities is ₹1,216 Mil. Kilitch Drugs (India)'s overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Total Current Liabilities is ₹1,216 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹184.24 is trading 18.5% below its estimated GF Value™ of ₹226.20. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Total Current Liabilities: ₹1,216 Mil
  • GF Value™: ₹226.20 vs. price of ₹184.24 (18.5% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
85GF Score

Get the complete analysis for NSE:KILITCH

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹184.24
Price
₹226.20
GF Value